Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson announces availability of improved Troponin I assay

Johnson and Johnson announces availability of improved Troponin I assay

5th October 2007

Johnson & Johnson (J & J) has announced the availability of an improved sensitivity Troponin I assay to help diagnose a heart attack, detect heart injury and predict the risk of future coronary events.

The biomarker troponin I will be available in the US, Europe and other international markets.

Cardiac troponin has previously been highlighted as the preferred biomarker for heart damage by the Joint European Society of Cardiology/American College of Cardiology Committee in 2000.

The new Vitros Troponin I ES Assay has been designed and integrated with the Vitros ECi /ECiQ System to help ensure accurate results using Intellicheck technology.

Heart attacks are one of the major causes of mortality in the world with physicians requiring more and more accurate cardiac troponin results to aid in the diagnosis of heart attacks or cardiac injury.

J & J has outlined that the Troponin I assay’s improved sensitivity will help to identify patients earlier and those that may benefit from specific therapeutic interventions.

Earlier this week, J & J announced that Health Canada had approved its Invega (paliperidone) for treatment of schizophrenia

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.